arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

RELMADA THERAPEUTICS, INC.

RLMD
$3.75 ▼ -0.43 (-10.29%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
59 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

RELMADA THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $421.4M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -5.7% ↗
FCF / Share $-0.09 ↗
Trailing P/E —
Price / Book 1.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

59-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$634.00
↑ +58.5% —
Net Income Profit after all expenses
$-19.05M
↓ -8.5% —
Operating Margin Operating profit as % of sales
-479.4%
↓ -5643.6% —
FCF / Share Free cash flow per share
$-0.09
↑ +50.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
13
Cash Quality ↑
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 59 quarters